Eli Lilly Launches Phase I Clinical Trial of Pan-KRAS Inhibitor LY4066434, Enrolling 750 KRAS-Mutant Patients

▎Armstrong

On September 23, 2024, Eli Lilly registered a Phase I clinical trial for the pan-KRAS inhibitor LY4066434 on the Clinicaltrials.gov website.

This Phase I clinical trial plans to enroll 750 patients with KRAS mutations to explore single-agent or multiple combination therapy regimens.

The combination therapy regimen includes EGFR monoclonal antibody, chemotherapy, PD-1 antibody, etc.

The enrollment criteria include patients with KRAS mutations, such as G12C, G12D, G12V, G12A, G12S, and G13D.

Summary

LY4066434 shows 74-108 fold selectivity for NRAS and HRAS. In China, companies like Jacobio have also developed pan-KRAS inhibitors and have already filed an IND.